Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

  1. Abou-Alfa, G.K.
  2. Lau, G.
  3. Kudo, M.
  4. Chan, S.L.
  5. Kelley, R.K.
  6. Furuse, J.
  7. Sukeepaisarnjaroen, W.
  8. Kang, Y.K.
  9. Dao, T.V.
  10. De Toni, E.N.
  11. Rimassa, L.
  12. Breder, V.
  13. Vasilyev, A.
  14. Heurgué, A.
  15. Tam, V.C.
  16. Mody, K.
  17. Thungappa, S.C.
  18. Ostapenko, Y.
  19. Yau, T.
  20. Azevedo, S.
  21. Varela, M.
  22. Cheng, A.-L.
  23. Qin, S.
  24. Galle, P.R.
  25. Ali, S.
  26. Gupta, C.
  27. Makowsky, M.
  28. Kurland, J.F.
  29. Negro, A.
  30. Sangro, B.
  31. Show all authors +
Journal:
Future oncology (London, England)

ISSN: 1744-8301

Year of publication: 2023

Volume: 19

Issue: 38

Pages: 2505-2516

Type: Review

DOI: 10.2217/FON-2023-0486 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus